echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Eur Radiol: How effective is palliative TACE treatment in patients with hepatocellular liver cancer who combine blood vessels?

    Eur Radiol: How effective is palliative TACE treatment in patients with hepatocellular liver cancer who combine blood vessels?

    • Last Update: 2021-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Primary malignant liver tumors are the 6th most common tumor and the 4th largest global cause of cancer-related death;
    the risk of blood vessels visible to the naked eye and metastasis in the liver and throughout the body increased significantly.
    if the blood vessels are placed but not, the median survival period may be 2-4 months.
    HCC, which combines blood vessels visible to the naked eye, is classified as a late HCC in the BCLC grading system.
    same time, HCC patients with combined vascular stress were less effective at receiving Solafini treatment, less toerable and less follow-up to treatment.
    arterial chemotherapy embolism (TACE) is often used as a palliative care treatment for such patients.
    , however, what are the benefits of HCC treatment for combined blood vessels being treated with TACE? A paper published recently on Eur Radiol called A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or vena cava evaluates the effectiveness and safety of HCC patients with HV or IVC-infested TACE through hepatic arterial chemotherapy embolism (TACE) and establishes a total survival prediction model.
    this study retrospectively analyzed data from patients who received TACE as a first-line treatment for liver cancer-infringing HIV or IVC between 1997 and 2019.
    .51-year-old HCC patients with combined hepatic venous thrombosis were treated with TACE before and after the results of the image study showed that this study included data on 296 patients (data from 1997-2006 to form a training queue, n s 174; Data for 2007-2019 make up the validation queue, n s 122).
    the median survival time of patients after TACY was 7.3 months, and objective expected results were achieved in 34.1% of patients.
    multivariate Cox analysis of the training queue identified five pre-treatment factors (maximum tumor size of 10 cm, immersion HCC, combined gate vein immersion, liver metastasis, and ECOG performance status1), which can be used to create predictive models of total survival.
    low risk group (risk sum: 0-3) and high risk group (risk sum: 4-7) have a median total survival time of 14 and 4.2 months in the validation queue, respectively.
    the time-dependent ROC curve applied to the total survival prediction model of the validation queue shows acceptable AUC values (0.723 and 0.667 at 6 months and 1 year, respectively).
    picture. According to the Kaplan-Meier graph of the total lifetime of the post-TACE treatment response. Validate the Kaplan-Meier graph of the group's total lifetime. In the training group and the validation group total lifetime dependence ROC curve this study showed that TACE was effective in liver cancer patients who partially violated HV or IVC.
    predictive model helps to screen patients who are treated with TACE.
    origin: Hee Ho Chu, Seng-Yong Chun, Jin Hyoung Kim, et al. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. PMID:33241523DOI:10.1007/s00330-020-07536-8shaosai Source: MedSci Original Copyright Statement: all noted on this website "Source: Metz Medicine" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Mays Medical, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Met Medical".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.